ZNTL Stock — Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc. (ZNTL)

Updated October 16, 2026.

ZNTL is a Stock. Total return is -90.8% over the past 6.5 years, 327.0 points behind SPY at 236.2%.

Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule cancer therapies, with its lead candidate azenosertib currently in Phase 3 trials for ovarian cancer and other solid tumors. The company does not currently pay distributions. This security appeals to investors seeking exposure to early-stage oncology drug development with high risk and potential for significant gains upon successful clinical advancement or partnership deals.

ZNTL performance versus SPY

Price and return data through 2026-10-16.

Total return is -90.8% over the past 6.5 years, 327.0 points behind SPY at 236.2%. Over the past year its total return — price change plus distributions reinvested — is 36.5%. Its deepest 1-year drawdown was 67.8%.

ZNTL key facts

Asset type

Stock

Asset class

Equity

Inception date

04/03/2020

Distribution frequency

None

Last close

$2.13 (as of 2026-10-16)

Market cap

$208,999,677

Average volume

1101751.0

Beta

1.938

Payout ratio

0.0%

EPS

$-1.96

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ZNTL risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 67.8%.

Who may consider ZNTL — and who may not

It is a weaker fit for investors who need monthly cash flow (ZNTL does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ZNTL

• All tickers starting with Z

Tagged: Healthcare.

Frequently asked questions